Let's talk about your next study New study? Request a quote →
Loading...
Intracellular Cytokine Staining (ICS) Assay Services

Intracellular Cytokine Staining (ICS) Assay Services

Cytokine production, degranulation, and memory phenotype read in the same antigen-specific CD4+ and CD8+ T cells by multiparameter flow cytometry

A count of cytokine-secreting cells, or a cytokine concentration in plasma or culture supernatant, can show how large an antigen-specific T-cell response is without showing which T cells made it or what else those cells do. Intracellular cytokine staining (ICS) addresses this by blocking secretion during a short stimulation, so that cytokines accumulate inside the cells that make them. Each cell is then stained for surface and intracellular markers and read by flow cytometry. The result is the frequency of cells carrying each function, reported as a percentage of CD4+ or CD8+ T cells and of their memory subsets, together with the combinations of functions that single cells carry. Two candidates or doses can raise responses of similar size that differ in which T cells respond and how many functions each cell carries. Reading the identity and the function of responding cells together gives your program a basis for comparing responses across arms and timepoints on their quality as well as their magnitude.

Accelevir is an ICS CRO in Baltimore, Maryland, running multiparameter ICS panels that read cytokines, degranulation, and memory phenotype on the same cells from a single stimulation. ICS draws on the same bank of cells as our ELISpot, FluoroSpot, proliferation, and killing assays, and one scientific team carries your work from preclinical studies through clinical trials. ICS assays supporting clinical trials are analytically qualified under our quality management system, with qualification documentation available to support regulatory filings.

What ICS assay services does Accelevir offer?

Accelevir’s ICS assay services measure antigen-specific T-cell function by flow cytometry in preclinical and clinical programs, from panel design and qualification through sample testing and reporting.

01

Established and custom ICS panels that read IFN-γ,

IL-2, TNF-α, MIP-1β, granzyme B, the degranulation marker CD107a, and the activation marker CD40L across CD4+ and CD8+ T cells and their memory subsets, or a panel built around the functions your study needs

02

HIV-1 ICS with qualified cross-clade overlapping peptide pools covering Gag,

Pol, Env, and Nef, for HIV-specific CD4+ and CD8+ T-cell responses

03

Innate ICS for cytokine responses of monocytes,

dendritic cells, and other innate cells, such as responses to an adjuvant or to an RNA payload and its delivery vehicle

04

Custom stimulation with commercially available or client-provided peptide pools,

including a pool you supply or specify, which we qualify as part of the project

05

Multi-species ICS for human samples and for any non-human primate (NHP) or rodent species with available reagents,

with each panel built for its species

06

Cell preparation and biobanking,

including PBMC isolation from whole blood with rapid-turnaround processing on receipt, isolation of cells from lymph node and spleen, cryopreservation, and storage from collection to analysis

07

Multi-site sample quality,

with PBMC isolation harmonized across collection sites and qualification of site vendors or operators for viable PBMC cryopreservation and sterility, so cryopreserved material from every site can be read as one dataset rather than several site-specific ones

08

Larger studies and clinical trials,

most readily through batched testing of cryopreserved samples

09

Method transfer and bridging,

with transfer and qualification of a sponsor-developed ICS assay, and bridging and comparability studies that let results from your earlier method be read next to results from ours

Plan your ICS panel with a scientist

How Your ICS Study Runs

We run each ICS study in five steps.

01

Scope the study

02

Qualify the panel

03

Arrange sample and data transfer

04

Test the samples

05

Receive your data

Scope the study

You state the modality, species, sample type, timepoints, and the decision the data must support. An Accelevir scientist defines the panel, stimulation conditions, controls, and sample requirements with your team and sends an itemized quote that becomes your Statement of Work.

Qualify the panel

Before study samples are tested, we titrate the antibodies for your species and sample type, confirm the stimulation conditions with the positive and negative controls, and fix the criterion for a positive response. Where the study supports a clinical trial, we analytically qualify the panel under our quality management system.

Arrange sample and data transfer

We set up shipments from your sites and the data transfer plan with you.

Test the samples

We thaw cryopreserved PBMCs or process fresh samples on receipt, measure viability and recovery, then stimulate, stain, and acquire each sample under the agreed conditions.

Receive your data

We deliver a written report and data package, and our scientists review the results with your team.

How does intracellular cytokine staining work?

ICS works by stimulating T cells and adding protein transport inhibitors during stimulation, so cytokines made in response stay inside the cell, where antibodies detect them after fixation and permeabilization. The method, developed in the 1990s, rests on the observation that blocking secretion lets a cytokine accumulate to levels flow cytometry can read in single cells, alongside the markers that say which cells they are.

We stimulate PBMCs with the antigen alongside a DMSO vehicle control and positive controls. For human samples, the positive controls are typically the CEF and CEF/TA peptide pools, which recall responses to common viral and vaccine antigens in CD8+ and CD4+ T cells. An antibody to CD107a is present from the start, so that it labels cells that degranulate during stimulation. Stimulations of 4, 6, and 18 hours are all typical, with the length chosen for the stimulus and the markers a study reads. In a 6-hour stimulation, for example, we add brefeldin A and monensin after the first 2 hours, so the cells spend the remaining 4 hours under the secretion block. Where a study calls for it, we add co-stimulation with antibodies to CD28 and CD49d, which can lower the activation threshold of some memory T cells.

Staining begins with a viability dye, because dead cells can bind antibodies nonspecifically and have been reported to inflate an apparent antigen-specific response. We then block Fc receptors, stain surface markers, and fix the cells before permeabilizing them and staining the intracellular targets. Where the schedule of a run calls for it, we hold the fixed cells at 4°C overnight before permeabilization, a step that serves timing rather than the method itself. We acquire samples by spectral flow cytometry, which records the full emission spectrum of every fluorochrome and separates their signals by unmixing against single-stain reference controls, so one panel can carry the lineage, memory, and functional markers together. We add sample-specific unstained controls to account for each sample’s autofluorescence.

We analyze every sample in a study against one gating hierarchy, agreed with you at scoping: acquisition stability over time, lymphocytes, single cells, viable cells, and CD3+ T cells, then CD4+ and CD8+ T cells, their memory subsets, and each function within each subset. Gating is a recognized source of variability in ICS between laboratories, so applying one hierarchy across arms, timepoints, and sites lets the results be read as one dataset.

How does intracellular cytokine staining work?

ICS panel design for CD4+ and CD8+ T cell function

Our Laboratory and Scientific Team

An ICS panel combines lineage, memory, and functional markers, so each function is read in CD4+ and CD8+ T cells and in their memory subsets. In our established human panel, CCR7 and CD45RA define naive, central memory, effector memory, and terminally differentiated effector memory cells.

The functions describe different parts of a response. IFN-γ, TNF-α, and IL-2 report the cytokine profile, MIP-1β has been reported among the functions most often induced in HIV-specific CD8+ T cells, and CD107a marks degranulation. CD40L (CD154) marks recently activated CD4+ T cells, including some that make none of the panel’s cytokines. Granzyme B is stored in the granules of differentiated cytotoxic T cells, so its level can reflect content present before stimulation as well as any change during it.

We build custom panels around the functions a study needs, such as additional cytokines, exhaustion or activation markers, or a detection reagent for engineered cells. Innate ICS panels assign cytokines such as IL-1β, IL-6, and TNF-α to monocytes, dendritic cells, and other innate cells, with the stimulus chosen for the agent under study. For NHP and rodent studies, we follow a procedure similar to the one for human samples, but we build the panel from antibody clones that react with the species and scope the markers and controls with you. The controls and stimulation conditions set for a panel typically carry over to later studies that use the same species and sample type.

How a positive ICS response is called

An ICS response is positive when the frequency of cells carrying a function after antigen stimulation exceeds the matched vehicle control by a criterion fixed before testing. Background in the vehicle control differs between donors and between functions, so we recommend reporting each result after subtraction of that donor’s own control. We can also deliver the raw FCS files for your team’s own analysis. We fix the criterion for the antigens and sample type before study samples are tested and keep it for every batch of the study. Where you want it, we also run positive-control PBMCs from a characterized donor, typically ones you supply, alongside study samples, so drift between batches can be tracked over the life of a trial. The lowest response a study can call depends on its background, the number of cells acquired, and that criterion. Functions expressed by few cells vary more from run to run than abundant ones, so qualification assesses precision marker by marker, and the analysis plan names the readouts reported for each study.

Vehicle control
Stimulated
Criterion, fixed before testing

A response is called positive only above the criterion, after subtracting the donor’s own control.

How does ICS measure polyfunctional T cell responses?

ICS measures polyfunctionality by asking, cell by cell, which combination of functions each antigen-specific T cell carries, using Boolean gating across every function in the panel. Because every function is read on the same cell, ICS can separate a cell that makes IFN-γ, IL-2, and TNF-α together from three cells that each make one, and assign each combination to CD4+ or CD8+ T cells and to a memory subset.

Polyfunctional T-cell responses have been associated with control of HIV and with vaccine-mediated protection in preclinical models, although the relationship between polyfunctionality and outcome is context-dependent and not fully established. Where a study calls for polyfunctional analysis, we report the frequency of each combination after background subtraction, so the full profile of functions can be compared between arms or timepoints rather than one cytokine at a time.

Single T cell IFN-γ IL-2 TNF-α CD107a

Boolean gating across every function separates one cell making three cytokines from three cells making one each.

How does ICS compare with ELISpot and FluoroSpot?

ICS shows which T cells responded and which functions each carries, while ELISpot and FluoroSpot count the cells that secrete one or several analytes, without phenotype. ELISpot counts the cells that secrete a cytokine onto a capture membrane. It is generally considered more sensitive than ICS for weak responses and typically uses fewer cells per condition, so it suits questions of frequency when responders are rare and sample is limited. FluoroSpot adds how many of those cells secrete several analytes at once.

ICS assigns each response to CD4+ or CD8+ T cells and to a memory subset, and it reads functions that are not secreted, such as degranulation and CD40L expression. Accelevir scientists settle the combination of readouts with you at scoping.

ICS

Which T cells responded, and which functions each carries

ELISpot

Counts the cells that secrete a cytokine

FluoroSpot

How many cells secrete several analytes at once

What applications use ICS in preclinical studies and clinical trials?

ICS shows which T cells respond to a vaccine, biologic, cell therapy, or infection and how that response changes over time, in preclinical studies and clinical trials alike. We plan ICS around your study’s sampling or visit schedule and can run it at each timepoint alongside our other immune and molecular readouts.

ICS testing by program area

Program What we measure
Cell Therapy (CAR-T, TCR-T, and NK)
Cytokine production and degranulation by product cells on engagement with their target antigen, assigned to CD4+ and CD8+ subsets for T-cell products
Gene Therapy (AAV and lentiviral)
Whether T-cell responses to the AAV capsid or the transgene product sit in CD4+ or CD8+ T cells, and which functions they carry
Gene & RNA Editing
The subset and functions of T cells responding to the editing enzyme, such as Cas9
RNA Therapeutics
Innate cytokine responses to the RNA payload and its delivery vehicle, assigned to monocytes, dendritic cells, and other innate cells, and T-cell responses to an encoded protein
Vaccines (mRNA, viral vector, protein subunit, conjugate, inactivated, and live attenuated; prophylactic and therapeutic)
CD4+ and CD8+ T-cell responses to the vaccine antigen, their polyfunctional profiles and memory subsets, and Th1 cytokine bias, with other cytokines added by custom panel
Antibody & Bispecific Therapeutics
T-cell activation by T-cell engagers in ex vivo mechanism-of-action studies, read as cytokine production and degranulation by CD4+ and CD8+ subsets
Antivirals
Virus-specific CD4+ and CD8+ T-cell responses during and after treatment, including HIV-1

HIV-1 ICS for cure and remission research

HIV-specific T-cell function is a central readout in HIV-1 cure and remission research, where interventions aim to strengthen responses that may help control virus after antiretroviral therapy (ART) is interrupted. Trials that stop ART in an analytical treatment interruption (ATI) have measured these responses by ICS before and during the interruption. We run HIV-1 ICS with qualified cross-clade overlapping peptide pools covering Gag, Pol, Env, and Nef on cryopreserved PBMCs from people with HIV (PWH). We have qualified ICS and antigen-induced T-cell proliferation together on the same pools. We can qualify other HIV-1 pools as a study needs them. The panel assigns each response to CD4+ or CD8+ T cells and their memory subsets. Reading degranulation, granzyme B, and CD40L alongside the cytokines can help show whether responses that persist on ART carry the functions that have been associated with control of HIV. HIV-1 ICS typically uses about 1 million viably cryopreserved PBMCs for each stimulation condition and replicate, so a sample tested in singlicate needs a minimum of about 6 to 10 million, and we set requirements with you per project. Our HIV-1 antigen-specific response assays cover HIV-1 ELISpot, ICS, and proliferation as one program.

Cross-clade overlapping peptide pools

Gag Pol Env Nef
≈1M viable PBMCs per stimulation condition
6–10M per sample tested in singlicate

What ICS Does and Does Not Capture

An ICS readout describes what antigen-specific T cells make during a short stimulation and which cells they are, and it leaves several properties of the response to other assays.

What it captures

What it does not capture

Our ICS Laboratory and Scientific Team

Our scientists bring experience in virology, HIV, and immuno-oncology, and Accelevir designs assays to detect rare signals. We have supported more than 100 clinical studies, dozens of them interventional clinical trials.

We support ICS work across the seven program areas we serve: Cell Therapy (CAR-T, TCR-T, and NK), Gene Therapy (AAV and lentiviral), Gene & RNA Editing, RNA Therapeutics (siRNA, ASO, and non-vaccine mRNA), Vaccines (prophylactic and therapeutic), Antibody & Bispecific Therapeutics, and Antivirals.

We support clinical trials under the comprehensive quality management system of our CAP-accredited, CLIA-certified laboratory, a system CAP inspects as part of our accreditation. Within it, we stimulate, stain, and analyze ICS samples under documented standard operating procedures, and we host sponsor audits. ICS assays supporting clinical trials are analytically qualified under our quality management system, with qualification documentation available to support regulatory filings. All samples are processed in our BSL-2+ laboratory, which adds enhanced biosafety practices to BSL-2 containment for work with bloodborne pathogens and viral vectors.

We coordinate sample shipments from clinical sites and in-life partners, and we receive and track every sample under our quality management system. A chain-of-custody record follows each sample from receipt, and quality assurance reviews every report before it reaches you. Data transfer follows specifications built to your requirements, with the format and schedule agreed before the first samples arrive. Cryopreserved material leaves our laboratory on dry ice or, preferably, in a liquid nitrogen dry shipper.

Our laboratory is scientist-run. One team works alongside yours from protocol design to final report, reviewing the protocol with you before testing and the results with you after it, and you have direct access to the scientists running your samples.

About Accelevir

Function and phenotype in one panel

One multiparameter panel reads cytokines, degranulation, and memory phenotype on the same cells, so the subsets carrying each function are identified directly rather than inferred across separate assays.

Frequency, function, and expansion from one bank of cells

We can run ICS with ELISpot or FluoroSpot and antigen-induced T-cell proliferation on the same PBMCs, so how many cells respond, what they make, and whether they can expand are read together.

Preclinical to clinical with one team

Moving a method from a preclinical vendor to a clinical laboratory can mean requalifying it mid-program. We partner with the vivarium of your choice for mouse and NHP studies, then carry the work into analytically qualified testing for clinical trials with the same scientists.

Talk with our scientific team

FAQ

Frequently Asked Questions

What is an intracellular cytokine staining (ICS) assay?

An intracellular cytokine staining (ICS) assay is a flow cytometry method that detects cytokines inside individual T cells after a short stimulation in which protein transport inhibitors block their secretion. Staining the same cells for surface markers assigns each cytokine to CD4+ or CD8+ T cells and their memory subsets, and results are reported as the percentage of each subset producing each cytokine or combination of cytokines.

How many cells does an ICS assay need?

An Accelevir ICS assay typically uses 0.5 to 1 million PBMCs per stimulation condition. Total input depends on the number of antigens, controls, replicates, and timepoints in the design, and Accelevir scientists scope the requirement with you before the study begins.

Which samples and species can you test by intracellular cytokine staining?

Accelevir runs ICS on samples from human studies and from non-human primate (NHP) and rodent studies in any species with available reagents. Samples can arrive as fresh or cryopreserved PBMCs, as whole blood from which we isolate PBMCs, or, for human, NHP, and mouse studies, as cells isolated from spleen or lymph node. For NHP and rodent studies, Accelevir builds the panel for the species. We scope the sample format with you for your assay and timepoints.

How are ICS assays qualified, and can they run as research-use-only?

For ICS panels that support clinical trials, Accelevir completes analytical qualification for the antigens, species, and sample type before study samples are tested. Qualification typically covers post-thaw viability and recovery, antibody titration, the stimulation conditions, stability after staining, and precision within and between runs, assessed marker by marker. Preclinical and discovery-stage work can run as research-use-only when the sponsor does not need qualification documentation, and Accelevir still sets the controls and positivity criterion before testing.

Can ICS be run on cryopreserved PBMCs from multi-site clinical trials?

Yes, Accelevir runs ICS on cryopreserved PBMCs, which lets samples from every site and timepoint be tested in batches under one protocol and one gating hierarchy. A multi-laboratory study found that cryopreserved PBMCs may give slightly more consistent ICS results than shipped whole blood. Accelevir measures viability and recovery on every sample after thaw.

What data do we receive at the end of an ICS study?

A typical Accelevir ICS report gives the background-subtracted frequency of each function in CD4+ and CD8+ T cells and their memory subsets, for each stimulation condition. Accelevir reports each frequency as a percentage of the parent population, with median fluorescence intensity, event counts, and the response call against the study’s positivity criterion, and adds each combination of functions where the design includes polyfunctional analysis. The report also gives a methods summary, every sample’s viability and recovery, and the gating strategy. Accelevir agrees the report’s final contents with you at scoping and delivers FCS files on request.

Can ICS data be combined with other readouts from the same study?

Yes, Accelevir can interpret ICS results next to ELISpot or FluoroSpot, proliferation, killing, and dPCR or qPCR data from the same study participant and timepoint. Choosing the readouts together at scoping lets one preparation of cells serve several questions.

How long does an ICS study take, and what sets its cost?

An Accelevir ICS study’s length and cost depend on the number of samples, antigens, and timepoints, whether the panel needs qualification first, and how samples are batched. Accelevir scientists scope these with you before sending an itemized quote.

How do we start an ICS project?

An ICS project with Accelevir starts with the project form and a scoping conversation about your antigens, species, sample numbers, and timepoints.

Match the ICS Panel to Your Study's Question

Complete the project form with your antigens or peptide pools, species and sample type, timepoints, sample availability, and the question your next milestone depends on. The Accelevir scientist who will scope your study replies with a recommended panel for the T-cell functions and subsets that matter to you, alone or with ELISpot, FluoroSpot, proliferation, or molecular endpoints, and an itemized quote matched to your study design. If you are transferring an existing ICS assay, include its protocol and any qualification report.

Accelevir Diagnostics, LLC is a CAP-accredited, CLIA-certified laboratory. Services are provided for research use in support of clinical and preclinical studies and are not intended for diagnostic, therapeutic, prognostic, or patient-management use.